Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Jun 2;17(6):e0269275. doi: 10.1371/journal.pone.0269275

Analysis of the saliva metabolic signature in patients with primary Sjögren’s syndrome

Zhen Li 1, Yue Mu 1, Chunlan Guo 1, Xin You 2, Xiaoyan Liu 3, Qian Li 1,*, Wei Sun 3,*
Editor: Timothy J Garrett4
PMCID: PMC9162338  PMID: 35653354

Abstract

Background

The saliva metabolome has been applied to explore disease biomarkers. In this study we characterized the metabolic profile of primary Sjögren’s syndrome (pSS) patients and explored metabolomic biomarkers.

Methods

This work presents a liquid chromatography-mass spectrometry-based metabolomic study of the saliva of 32 patients with pSS and 38 age- and sex-matched healthy adults. Potential pSS saliva metabolite biomarkers were explored using test group saliva samples (20 patients with pSS vs. 25 healthy adults) and were then verified by a cross-validation group (12 patients with pSS vs. 13 healthy adults).

Results

Metabolic pathways, including tryptophan metabolism, tyrosine metabolism, carbon fixation, and aspartate and asparagine metabolism, were found to be significantly regulated and related to inflammatory injury, neurological cognitive impairment and the immune response. Phenylalanyl-alanine was discovered to have good predictive ability for pSS, with an area under the curve (AUC) of 0.87 in the testing group (validation group: AUC = 0.75).

Conclusion

Our study shows that salivary metabolomics is a useful strategy for differential analysis and biomarker discovery in pSS.

Background

Sjögren’s syndrome (SS) is a multisystem autoimmune disease characterized by hypofunction of salivary and lacrimal glands and possible systemic multiorgan manifestations [1]. SS is a complex and heterogeneous disorder characterized by different clinical subsets [2], such as thrombocytopenia [3], leukopenia [4], lymphoma [5], interstitial pneumonia [6], renal tubular acidosis [7], and peripheral nerve involvement [8]. In the era of personalized medicine, new biomarkers are required to diagnose SS early, to define different disease subsets, to direct patients’ clinical management and to monitor disease progression [9].

Saliva is a complex fluid containing a variety of metabolites, proteins, mRNAs, DNAs, enzymes, hormones, antibodies, antimicrobial constituents, growth factors and other molecules that may be associated with disease phenotypes [10, 11]. Compared to blood, saliva is easily, rapidly and noninvasively collected [12, 13]. Salivary gland dysfunction in primary Sjögren’s syndrome (pSS) patients inevitably leads to changes in salivary components, and the pathogenesis of the disease can thus be inferred from changes in saliva. Many previous studies have focused on saliva proteomic, transcriptomic and genomic biomarkers for pSS [14, 15]; however, a sensitive and specific biomarker in this fluid source has not yet been available.

Metabolites, which are important indicators of physiological or pathological states, can provide information for the identification of early and differential markers of disease and help in understanding disease occurrence and progression [16]. Overall, saliva metabolomics has become a useful strategy for identifying biomarkers for oral squamous cell carcinoma [17, 18], periodontal diseases [19], oral lichen planus [20], oral leukoplakia [21] and cardiovascular disease [22]. In addition, a few metabolomics studies have recently reported salivary [2325] sample biomarkers for pSS diagnosis. Both Mikkonen JJ and Herrala M used nuclear magnetic resonance (NMR) spectroscopy to analyze the saliva metabolome, and the levels of choline, taurine, alanine, glycine, phenylalanine and proline were found to be higher in patients with pSS than in controls [24, 25]. In another study, the saliva of 12 pSS patients was assessed by gas chromatography–mass spectrometry (GC–MS), and glycine, tyrosine, uric acid and fucose were found to be downregulated [23].

Ultra-performance liquid chromatography coupled with high-resolution mass spectrometry (UPLC-HRMS) is considered an appropriate technique for metabolomics studies, especially for large-scale untargeted metabolic profiling [26]. However, the use of the UPLC-HRMS method for detecting salivary metabolites in pSS patients has not been reported. The major objective of our study was to discover potential salivary biomarkers to distinguish patients with pSS from healthy controls by UPLC-HRMS.

Materials and methods

Ethics statement

The investigation protocol was approved by the Institutional Review Board of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Project No:047–2019. Verbal consent forms indicating agreement to serve as saliva donors for the experiments were obtained from all study subjects before participation in the study (S1 File).

Sample collection

This trial focused on pSS. A total of 32 pSS and 38 healthy control saliva samples were collected and randomly divided into two groups: the test group included 20 pSS patients and 25 healthy human adults, and the validation group included 12 pSS patients and 13 healthy controls. The participants were recruited from July 2019 to January 2020 from the Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital. These groups did not include subjects with any acute condition. All 32 patients with pSS were recruited according to the 2016 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for pSS [1] by a rheumatologist to confirm the diagnosis according to medical history, clinical manifestations and examination and that pSS was not secondary to other connective tissue diseases (CTDs). The detailed demographics and disease pathology of the patients are shown in Table 1.

Table 1. Demographics and clinical characteristics of the pSS patients and healthy control subjects.

Test group Validation group
Characteristic pSS patients HCs pSS patients HCs
Number of samples 20 25 12 13
Age (x- ± s) 39.7±10.9 40.6±12.8 41.4±12.2 44.1±12.7
Sex (F/M) 17/3 23/2 10/2 12/1
Anti-SSA/Ro- antibody positivity 16/20 9/11
Anti-SSB/La- antibody positivity 3/20 1/11
Immunoglobulin G positivity 12/20 6/12
Labial gland biopsy positivity 14/17 9/10

pSS- primary Sjögren’s syndrome, HCs- healthy controls, SSA- Sjögren’s syndrome-related antigen A, SSB- Sjögren’s syndrome-related antigen B, p < 0.05 for Wilcoxon test for pSS patients and HCs.

Unstimulated whole saliva samples were collected by having the participants spit for 15 min into a container between 9:00 and 11:00 a.m. The subjects were requested to refrain from eating, drinking, smoking or oral hygiene procedures for at least 1.5 hr prior to unstimulated whole saliva collection and to rinse their mouth with water prior to sample collection. The samples were transported to the laboratory on ice and centrifuged at 1500 × g for 15 min at 4°C to remove shed cell debris and residue, and then the supernatants were frozen immediately and stored at -80°C until analysis [23].

Sample preparation

For saliva metabolomics, acetonitrile (200 μL) was added to each saliva sample (200 μL), and the mixture was vortexed for 30 s and centrifuged at 14,000 × g for 10 min. The supernatant was dried under vacuum and reconstituted with 200 μL of 2% acetonitrile. The quality control (QC) sample was a pooled saliva sample prepared by mixing aliquots of all samples across the two groups to be analyzed and was therefore globally representative of the whole sample set. The QC samples were injected every ten samples throughout the analytical run to provide a set of data from which method stability and repeatability could be assessed.

UPLC-HRMS analysis

UPLC-HRMS analyses of samples were conducted using a Waters ACQUITY H-class LC system coupled with an LTQ-Orbitrap Velos pro mass spectrometer (Thermo Fisher Scientific, MA. USA). Saliva metabolites were separated with a 17-min gradient using a Waters HSS C18 column (3.0× 100 mm, 1.7 μm) at a flow rate of 0.3 mL/min. Mobile phase A was 0.1% formic acid in H2O, and mobile phase B was acetonitrile. Saliva metabolites were separated with a gradient as follows: 0–2 min, 2% solvent B; 2–5 min, 2–55% solvent B; 5–15 min, 55–100% solvent B; 15–20 min, 100% solvent B; 20–20.1 min, 100–2% solvent B; and 20.1–29 min, 2% solvent B. The column temperature was set at 45°C. Full MS acquisition was performed from 100 to 1000 m/z at a resolution of 60 K. The automatic gain control (AGC) target was 1× 106, and the maximum injection time (IT) was 500 ms. UPLC targeted-MS/MS data were acquired at a resolution of 15 K with an AGC target of 5× 104, a maximum IT of 250 ms, and an isolation window of 3 m/z. The collision energy was optimized as 20, 40, 60 or 80 for each target with higher-energy collisional dissociation (HCD) fragmentation. The injection order of the saliva samples was randomized to reduce experimental bias.

Statistical analysis

Raw data files were processed by Progenesis QI (Version 2.0, Nonlinear Dynamics) software based on a previously published identification strategy, which included sample alignment, peak picking, peak grouping, deconvolution, normalization by total compounds, and final information export [27]. To make features more comparable, further data preprocessing, including missing value estimation, log2 transformation and Pareto scaling, was carried out using MetaAnalyst 3.0 (http://www.metaboanalyst.ca). Variables missed in 50% or more of all samples were removed from further statistical analysis. Nonparametric tests (Wilcoxon rank-sum test) were employed to evaluate the significance of variables. False discovery rate (FDR) correction was used to estimate the chance of false positives and correct for the testing of multiple hypotheses. The adjusted p value (FDR) cutoff was set as 0.05. Pattern recognition analysis (principal component analysis, PCA; orthogonal partial least squares discriminant analysis, OPLS-DA) was performed using SIMCA 14.0 (Umetrics, Sweden) software. The differential variables selected met the following three conditions: (i) adjusted p < 0.05; (ii) fold change between the two groups >2; and (iii) variable importance in OPLS-DA projection (VIP) above 1. Exploratory ROC analysis and external biomarker validation were carried out using the “Biomarker discovery” module with the MetaboAnalyst 3.0 platform.

Potential biomarkers were further evaluated by receiver operating characteristic (ROC) analysis. The area under the ROC curve (AUC), an efficient indicator of model performance, was used as a metric to assess the sensitivity and specificity of the biomarkers. AUC values > 0.9 indicate high reliability of the model, 0.7 to 0.9 indicate moderate reliability, 0.5 to 0.7 indicate poor reliability, and AUC ≤ 0.5 suggests that the model prediction is not better than chance.

Metabolite annotation and pathway analysis

Metabolic pathways and predicted metabolites in the pathways were analyzed using the “Mummichog” algorithm based on the MetaboAnalyst 3.0 platform. Mummichog is a program written in python for analyzing data from high‐throughput, untargeted metabolomics, bypassing the tedious and challenging metabolite identification. It leverages the organization of metabolic networks to predict functional pathways directly from feature tables and generate a list of tentative metabolites annotations through functional activity analysis. Metabolite annotation was further determined from the exact mass composition, from the goodness of isotopic fit for the predicted molecular formula and from MS/MS fragmentation comparing hits with databases (HMDB http://www.hmdb.ca/), thus qualifying for annotation at MSI level II using Progenesis QI. For endogenous metabolites lacking a chemical formula, an accurate molecular mass was determined based on the calculated isotopic features and ion adducts. Detailed methods are listed in the Supplementary Methods.

Results

The workflow of our study is shown in Fig 1. Metabolite variation and pathway regulation associated with pSS were explored based on an analysis of metabolic profile differences between pSS and healthy controls. Potential biomarkers for pSS were further explored based on differential metabolites and validated using 10-fold cross-validation or external validation.

Fig 1. The workflow of our study.

Fig 1

Characteristics of the participants

All the pSS patients included in the study had either ocular and/or oral symptoms, and all were positive for one or more autoantibodies. The autoimmune antibody profiles revealed anti-Ro-/Sjögren’s syndrome A-antibody (anti-Ro/SSA) positivity in 73.5% (25/31) of the participants and anti-La-/Sjögren’s syndrome B-antibody (anti-La/SSB) positivity in 11.8% (4/31) of the participants. In total, 27 pSS patients underwent labial gland biopsy, with positive results in 23. Detailed information is shown in Table 1.

Quality control

To reduce experimental variations from the sampling process, standard sampling procedures, including sampling time and sampling processing, were performed by professionals. To ensure the repeatability and consistency of the metabolomics data, a quality control (QC) sample consisting of all samples was injected every ten or twelve sample injections. Principal component analysis was performed to evaluate the variation in samples. A good cluster of QC samples indicated good stability of the analytical platform (S1A Fig).

Distinction of pSS patients from healthy controls by saliva metabolomics

Based on UPLC-HRMS analysis, 2887 variables were quantified and analyzed from pSS and control saliva samples after QC filtering.

First, PCA was performed to explore the tendency of metabolic profiling variations between the healthy controls and pSS subjects (Fig 2A) and suggested apparent discrimination. Next, the OPLS-DA model achieved better separation for differential metabolite selection (R2X = 0.413, R2Y = 0.932, Q2 = 0.46, CV-ANOVA, p = 0.00070, Fig 2B). Permutation tests (100 times) were performed to confirm the stability and robustness of the supervised models presented in this study (intercept of Q2 = - 0.261, S1B Fig).

Fig 2. Comparison between pSS subjects and healthy controls.

Fig 2

(a) Score plot of the PCA-X model between pSS subjects (blue) and healthy controls (green). (b) Score plot of the OPLS-DA model between pSS subjects (blue) and healthy controls (green).

Overall, 676 features with a P value < 0.05 (351 upregulated and 325 downregulated features) were submitted for pathway enrichment analysis using the Mummichog algorithm. The results showed significant enrichment (p < 0.05) of several pathways, including tryptophan metabolism, tyrosine metabolism, carbon fixation, and aspartate and asparagine metabolism, etc. Metabolites involved in tryptophan metabolism and aspartate and asparagine metabolism were upregulated. Metabolites involved in carbon fixation were downregulated (Fig 3).

Fig 3. Pathway enrichment analysis of differential metabolites of pSS and healthy controls.

Fig 3

Further annotation of the top discriminatory features (p < 0.05; FC >2; VIP >1) determined by MS/MS evaluation identified 38 significantly differentially abundant metabolites (S1 Table; relative intensity plotted as a heatmap in Fig 4).

Fig 4. Relative intensity of differential metabolites in pSS subjects and healthy controls.

Fig 4

Notably, the number of metabolites derived from amino acids was upregulated, and many of them were dipeptides. These metabolites include phenylalanyl-alanine, tryptophyl-isoleucine, tyrosyl-phenylalanine, asparaginyl-valine, aspartyl-isoleucine and tyrosyl-hydroxyproline. Additional differential metabolites related to purine metabolites, included 8-hydroxyadenine and oxypurinol. All the metabolites were present at higher levels in pSS.

To evaluate the diagnostic accuracy of these differential metabolites for pSS, a predictive model for patient classification was constructed using each identified metabolite. All 38 metabolites had a potentially useful diagnostic value, with an AUC above 0.7, and 30 metabolites had a good diagnostic value, with an AUC above 0.8. Among the saliva metabolites, aspartyl-isoleucine had the highest area under the ROC curve for the diagnosis of pSS (0.88, p<0.001), and both the sensitivity and specificity reached 80%. Phenylalanyl-alanine for the classification of pSS patients and controls had an AUC of 0.87 for the test group, a sensitivity of 80%, and a specificity of 84%. To limit overfitting, the training set was subjected to 10-fold cross-validation to evaluate the stability and generalization of the metabolite. Further external validation using an independent sample set was carried out and achieved good performance with an AUC of 0.75, sensitivity of 75% and specificity of 85% (S2 Table and Fig 5).

Fig 5. Potential biomarker using phenylalanyl-alanine for pSS prediction from healthy controls.

Fig 5

(a) Relative intensity of metabolites in pSS patients and controls (test group). (b) ROC curve established using logistic regression (test group). (c) Relative intensity of metabolites in pSS patients and controls (validation group). (d) ROC curve in pSS patients and controls (validation group).

Discussion

Saliva is produced primarily by the major salivary glands, and the impaired secretion of the salivary glands can be described by the metabolites of saliva, which is an excellent diagnostic medium for clinical diagnostics [28]. In the present study, we conducted a comprehensive characterization of the saliva metabolome of 32 pSS patients and 38 healthy subjects. Our results suggest that the saliva metabolome can be used to differentiate pSS patients from healthy controls.

Whole saliva is a complex fluid containing a variety of substances, and changes in the levels of these substances are related to the pathogenesis of various diseases. However, the function of the salivary glands in patients with pSS is severely weakened, resulting in the volume of saliva being too small. Patients’ whole saliva up to 2 ml was collected for analysis over time to obtain a pre-normalization of saliva.

Reliable identification of features distinguishing biological groups in salivary metabolite fingerprints requires the control of total metabolite abundance. Normalizations to one index values (for example, creatinine for urine metabolomics), osmolality, and total compound (useful MS signals) were the commonly used normalization techniques for overcoming sample variability in fluids metabolomics. Previous researches have compared the effect of different normalization method on urine metabolomics study. It showed that the best performance was normalization to the total compound. The approach does not only correct for different urinary output, but it also accounts for injection variability (REF: Evaluation of dilution and normalization strategies to correct for urinary output in HPLC-HRTOFMS metabolomics.). In present study, we normalized the data using the method of “Normalize to useful MS signals” to reduce sample variation. However, it cannot completely solve the problem of pre-normalization. It is necessary to perform targeted and absolute quantitative analysis to solve this problem, which is our future project.

According to the LC-HRMS spectra of human saliva, we identified a total of 38 metabolites that could be used to significantly differentiate patients with pSS from healthy controls. Our results indicated that the most affected pathways included several amino acid metabolism pathways. Elevated levels of amino acid dipeptides and their products are pathogenic factors for neurological disorders, oxidative stress, and cardiovascular disease. Some amino acids regulate key metabolic pathways that are necessary for maintenance, growth, reproduction, immunity and inflammation [29].

One of the most important results of our study is that the number of metabolites, many of which were dipeptides, derived from tyrosine and phenylalanine metabolic pathways was upregulated in saliva samples. Consistent with our results, phenylalanine concentrations were significantly higher in salivary samples of pSS patients in previous studies, which were analyzed by H-NMR pectroscopy [25]. Phenylalanine hydroxylation to tyrosine, which can synthesize important neurotransmitters and hormones, is carried out by phenylalanine hydroxylase [30]. In recent studies, proteomic analysis revealed that tyrosine-protein phosphatase nonreceptor type 6 (PTPN6) was dysregulated in saliva and salivary glands in pSS murine models [31]. Receptor tyrosine kinase signaling appears to be disrupted in SS patients, potentially promoting the development of autoantibodies, lymphocytic infiltration, and overt disease [32]. This suggests that tyrosine and phenylalanine play a role in inflammatory injury in this disease.

Moreover, tryptophan metabolism was another significantly upregulated metabolic pathway in our study. Consistent with our results, the products involved in tryptophan metabolism are also changed in the blood and urine samples of pSS patients [33]. An imbalance in the synthesis of tryptophan metabolites has been associated with pathophysiologic mechanisms occurring in neurologic and psychiatric disorders [34, 35], in chronic immune activation [36] and in the immune escape of cancer [37, 38]. Previous results suggested that tryptophan metabolism regulated the immune response in pSS [39].

The results of differential metabolite identification suggested that disorded metabolism of aspartic is also involved in pSS. Aspartic acid is an excitatory amino acid and has strong excitatory effects on neurons. Elevated levels of aspartic acid and phenylalanine in the brain have been linked to behavioral and cognitive problems [40]. Distal sensory and sensorimotor neuropathies are the most common manifestations of peripheral nerve disease in pSS [41]. From our results, we speculate that elevated aspartic acid may be related to nervous system conditions in pSS.

Notably, the level of proline was elevated in saliva from pSS patients in our study, which is consistent with a previous study [24, 25, 33, 42]. Proline metabolism has complex roles in a variety of biological processes, including cell signaling, stress protection, and energy production [43]. Proline metabolic abnormalities affect the citric acid cycle and reduce cell metabolism in an inflammatory state, resulting in cartilage and bone damage [44]. Epstein-Barr virus nuclear antigen (EBNA)-1, a proline-rich sequence, was elevated significantly in patients with systemic lupus erythematosus (SLE) and pSS [45]. Research suggests that inhibiting proline metabolism and transport may be a useful therapeutic strategy against some pathogens.

We noticed that many dipeptides were upregulated. The lysosomal pathway, ubiquitination pathway and caspase pathway are major pathways of protein degradation. Lysosome-associated membrane protein 3(LAMP3) is classically associated with the lysosome, a main organelle central to autophagy. A previous study reported that in SS cases, the expression of LAMP3 was increased, which was related to apoptosis [46]. For the caspase pathway previous studies found that saliva levels of caspase-1 were significantly higher in SS patients, which can induce the production of apoptosis [47]. According to above studies, several important protein degradation pathways in SS were upregulated. Therefore, it was possible that protein degradation was increased in SS, which led to more dipeptides.

In addition to disturbances in amino acid metabolism, our study found abnormalities in purine metabolism. The related metabolites were oxypurinol and 8-hydroxyadenine. Disturbances in purine metabolism can cause gout, which manifests as arthritis due to the crystals produced in hyperuricemia [48]. A previous study found that the mRNA and protein levels of purinergic receptor P2X ligand-gated ion channel 7 (P2X7R) in pSS peripheral blood mononuclear cells were significantly higher than those in normal individuals [49] P2X7R participates in the pathogenesis of pSS. Activation of P2X7 is known to lead to processing and secretion of the proinflammatory cytokines IL-1β and IL-18 from monocytes/macrophages via activation of the NALP3 inflammasome, which is thought to play a role in a spectrum of inflammatory diseases [50]. Upregulation of purine metabolism indicates an inflammatory response in pSS patients.

This caught our attention because carbon fixation was abnormal in our study. This pathway is a cyclic reaction that consumes ATP and NADPH continuously and immobilizes CO2 to form glucose. However, there are no reports of abnormal carbon cycles in pSS patients. Human cohorts and animal models provide compelling data suggesting the role of the one-carbon cycle in modulating the risk of diabetes, adiposity [51] and fatty liver [52]. Studies have reported that pSS patients exhibit markedly higher prevalence rates of metabolic disorders, such as diabetes and dyslipidemia [53]. Therefore, carbon fixation imbalance may be associated with abnormal lipid metabolism in pSS.

Conclusion

In conclusion, our study demonstrates that saliva metabolites can be utilized for biomarker discovery in pSS. In our pilot study of pSS saliva metabolic profiling, we were able to distinguish the pSS group from the control group, and panels of metabolites were discovered to have potential value for pSS diagnosis. The potential biomarkers indicated that pSS metabolic disturbance might be associated with inflammatory injury, neurological cognitive impairment, immune response and abnormal lipid metabolism. Overall, our data will benefit the application of the saliva metabolome to disease biomarker discovery, potentially leading to new strategies for assessing the disease.

This work was a pilot study for pSS metabolic biomarker analysis. Further studies should expand the number of pSS patient samples and validate the potential metabolite biomarkers using targedted method, which is our future work. Additionally, further studies should expand the number of pSS patient samples and refine the metabolite profiles of pSS saliva, observe the changes in these biomarkers before and after treatment, and identify biomarkers associated with treatment efficacy, which will hopefully provide an important basis for clinical efficacy evaluation and prognosis prediction in pSS.

Supporting information

S1 Fig

(a) Tight clustering of QC samples indicated good stability of the analysis. (b) Platform 100 times permutation tests for the OPLS-DA model.

(TIF)

S1 Table. The metabolites related with pSS/control.

Fold change > 1 indicates a relatively higher concentration of the marker present in pSS patients, whereas < 1 indicates a relatively lower concentration of the marker compared with healthy control subjects.

(DOCX)

S2 Table. Receiver operating characteristic (ROC) analysis of potential pSS biomarkers.

Note: The sensitives and specificities were calculated at their best cutoff points.

(DOCX)

S1 File. PLOS One clinical studies checklist.

(PDF)

Acknowledgments

The authors thank all participants in this study. Study concept and design: Qian Li and Xin You. Patient recruitment: Xin You, Zhen Li, Yue Mu, Chunlan Guo. Data acquisition: Yue Mu, Zhen Li. Data analysis and interpretation: Xiaoyan Liu, Wei Sun. Manuscript writing: Zhen Li, Xiaoyan Liu. Approval of the final version: Wei Sun, Qian Li. All authors reviewed the manuscript before submission.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2017;69(1):35–45. doi: 10.1002/art.39859 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Vivino FB. Sjogren’s syndrome: Clinical aspects. Clin Immunol. 2017;182:48–54. doi: 10.1016/j.clim.2017.04.005 [DOI] [PubMed] [Google Scholar]
  • 3.Hu YH, Zhou PF, Long GF, Tian X, Guo YF, Pang AM, et al. Elevated Plasma P-Selectin Autoantibodies in Primary Sjögren Syndrome Patients with Thrombocytopenia. Med Sci Monit. 2015;21:3690–5. doi: 10.12659/msm.895144 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Cafaro G, Gerli R, Bartoloni E. Association Between Glandular Infiltrate and Leukopenia in Sjögren Syndrome (SS): Data From the Italian Research Group on SS (GRISS). J Rheumatol. 2020;47(12):1840–1. doi: 10.3899/jrheum.200328 [DOI] [PubMed] [Google Scholar]
  • 5.Retamozo S, Brito-Zerón P, Ramos-Casals M. Prognostic markers of lymphoma development in primary Sjögren syndrome. Lupus. 2019;28(8):923–36. doi: 10.1177/0961203319857132 [DOI] [PubMed] [Google Scholar]
  • 6.Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S. Pulmonary manifestations of Sjögren’s syndrome. Eur Respir Rev. 2016;25(140):110–23. doi: 10.1183/16000617.0011-2016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Goules A, Geetha D, Arend LJ, Baer AN. Renal involvement in primary Sjögren’s syndrome: natural history and treatment outcome. Clin Exp Rheumatol. 2019;118(3):123–32. [PubMed] [Google Scholar]
  • 8.Perzyńska-Mazan J, Maślińska M, Gasik R. Neurological manifestations of primary Sjögren’s syndrome. Reumatologia. 2018;56(2):99–105. doi: 10.5114/reum.2018.75521 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Cecchettini A, Finamore F, Puxeddu I, Ferro F, Baldini C. Salivary extracellular vesicles versus whole saliva: new perspectives for the identification of proteomic biomarkers in Sjögren’s syndrome. Clin Exp Rheumatol. 2019;118(3):240–8. [PubMed] [Google Scholar]
  • 10.Bigler LR, Streckfus CF, Dubinsky WP. Salivary biomarkers for the detection of malignant tumors that are remote from the oral cavity. Clin Lab Med. 2009;29(1):71–85. doi: 10.1016/j.cll.2009.01.004 [DOI] [PubMed] [Google Scholar]
  • 11.Schafer CA, Schafer JJ, Yakob M, Lima P, Camargo P, Wong DT. Saliva diagnostics: utilizing oral fluids to determine health status. Monogr Oral Sci. 2014;24:88–98. doi: 10.1159/000358791 [DOI] [PubMed] [Google Scholar]
  • 12.Henson BS, Wong DT. Collection, storage, and processing of saliva samples for downstream molecular applications. Methods Mol Biol. 2010;666:21–30. doi: 10.1007/978-1-60761-820-1_2 [DOI] [PubMed] [Google Scholar]
  • 13.Yeh CK, Christodoulides NJ, Floriano PN, Miller CS, Ebersole JL, Weigum SE, et al. Current development of saliva/oral fluid-based diagnostics. Tex Dent J. 2010;127(7):651–61. [PMC free article] [PubMed] [Google Scholar]
  • 14.Hu S, Wang J, Meijer J, Ieong S, Xie Y, Yu T, et al. Salivary proteomic and genomic biomarkers for primary Sjögren’s syndrome. Arthritis Rheum. 2007;56(11):3588–600. doi: 10.1002/art.22954 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Aqrawi LA, Galtung HK, Vestad B, Øvstebø R, Thiede B, Rusthen S, et al. Identification of potential saliva and tear biomarkers in primary Sjögren’s syndrome, utilising the extraction of extracellular vesicles and proteomics analysis. Arthritis Res Ther. 2017;19(1):14. doi: 10.1186/s13075-017-1228-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Nicholson JK, Wilson ID. Opinion: understanding ’global’ systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov. 2003;2(8):668–76. doi: 10.1038/nrd1157 [DOI] [PubMed] [Google Scholar]
  • 17.Ishikawa S, Sugimoto M, Kitabatake K, Sugano A, Nakamura M, Kaneko M, et al. Identification of salivary metabolomic biomarkers for oral cancer screening. Sci Rep. 2016;6:31520. doi: 10.1038/srep31520 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ishikawa S, Sugimoto M, Kitabatake K, Tu M, Sugano A, Yamamori I, et al. Effect of timing of collection of salivary metabolomic biomarkers on oral cancer detection. Amino Acids. 2017;49(4):761–70. doi: 10.1007/s00726-017-2378-5 [DOI] [PubMed] [Google Scholar]
  • 19.Mikkonen JJ, Singh SP, Herrala M, Lappalainen R, Myllymaa S, Kullaa AM. Salivary metabolomics in the diagnosis of oral cancer and periodontal diseases. J Periodontal Res. 2016;51(4):431–7. doi: 10.1111/jre.12327 [DOI] [PubMed] [Google Scholar]
  • 20.Yan SK, Wei BJ, Lin ZY, Yang Y, Zhou ZT, Zhang WD. A metabonomic approach to the diagnosis of oral squamous cell carcinoma, oral lichen planus and oral leukoplakia. Oral Oncol. 2008;44(5):477–83. doi: 10.1016/j.oraloncology.2007.06.007 [DOI] [PubMed] [Google Scholar]
  • 21.Wei J, Xie G, Zhou Z, Shi P, Qiu Y, Zheng X, et al. Salivary metabolite signatures of oral cancer and leukoplakia. Int J Cancer. 2011;129(9):2207–17. doi: 10.1002/ijc.25881 [DOI] [PubMed] [Google Scholar]
  • 22.Miller CS, Foley JD, Bailey AL, Campell CL, Humphries RL, Christodoulides N, et al. Current developments in salivary diagnostics. Biomark Med. 2010;4(1):171–89. doi: 10.2217/bmm.09.68 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kageyama G, Saegusa J, Irino Y, Tanaka S, Tsuda K, Takahashi S, et al. Metabolomics analysis of saliva from patients with primary Sjögren’s syndrome. Clin Exp Immunol. 2015;182(2):149–53. doi: 10.1111/cei.12683 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Herrala M, Mikkonen JJW, Pesonen P, Lappalainen R, Tjäderhane L, Niemelä RK, et al. Variability of salivary metabolite levels in patients with Sjögren’s syndrome. J Oral Sci. 2020;63(1):22–6. doi: 10.2334/josnusd.19-0504 [DOI] [PubMed] [Google Scholar]
  • 25.Mikkonen JJW, Herrala M, Soininen P, Lappalainen R, Seitsalo H. Metabolic profiling of saliva in patients with primary Sjögren’s syndrome. Metabolomics. 2013; 3: 128. doi: 10.4172/2153-0769.1000128 [DOI] [Google Scholar]
  • 26.Szymańska E, Saccenti E, Smilde AK, Westerhuis JA. Double-check: validation of diagnostic statistics for PLS-DA models in metabolomics studies. Metabolomics. 2012;8(Suppl 1):3–16. doi: 10.1007/s11306-011-0330-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zhang J, Yang W, Li S, Yao S, Qi P, Yang Z, et al. An intelligentized strategy for endogenous small molecules characterization and quality evaluation of earthworm from two geographic origins by ultra-high performance HILIC/QTOF MS(E) and Progenesis QI. Anal Bioanal Chem. 2016;408(14):3881–90. doi: 10.1007/s00216-016-9482-3 [DOI] [PubMed] [Google Scholar]
  • 28.Jarai T, Maasz G, Burian A, Bona A, Jambor E, Gerlinger I, et al. Mass spectrometry-based salivary proteomics for the discovery of head and neck squamous cell carcinoma. Pathol Oncol Res. 2012;18(3):623–8. doi: 10.1007/s12253-011-9486-4 [DOI] [PubMed] [Google Scholar]
  • 29.Wu G. Amino acids: metabolism, functions, and nutrition. Amino Acids. 2009;37(1):1–17. doi: 10.1007/s00726-009-0269-0 [DOI] [PubMed] [Google Scholar]
  • 30.Hommes FA, Lee JS. The effect of plasma valine, isoleucine and leucine on the control of the flux through tyrosine- and tryptophan-hydroxylase in the brain. J Inherit Metab Dis. 1990;13(2):151–5. doi: 10.1007/BF01799677 [DOI] [PubMed] [Google Scholar]
  • 31.Liang P, Zhu W, Lan T, Tao Q. Detection of salivary protein biomarkers of saliva secretion disorder in a primary Sjögren syndrome murine model. J Pharm Biomed Anal. 2018;154:252–62. doi: 10.1016/j.jpba.2018.03.023 [DOI] [PubMed] [Google Scholar]
  • 32.Witas R, Peck AB, Ambrus JL, Nguyen CQ. Sjogren’s Syndrome and TAM Receptors: A Possible Contribution to Disease Onset. J Immunol Res. 2019;2019:4813795. doi: 10.1155/2019/4813795 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Fernandez-Ochoa A, Borras-Linares I, Quirantes-Pine R, Alarcon-Riquelme ME, Beretta L, Segura-Carretero A, et al. Discovering new metabolite alterations in primary sjögren’s syndrome in urinary and plasma samples using an HPLC-ESI-QTOF-MS methodology. J Pharm Biomed Anal. 2020;179:112999. doi: 10.1016/j.jpba.2019.112999 [DOI] [PubMed] [Google Scholar]
  • 34.Mohajeri MH, Wittwer J, Vargas K, Hogan E, Holmes A, Rogers PJ, et al. Chronic treatment with a tryptophan-rich protein hydrolysate improves emotional processing, mental energy levels and reaction time in middle-aged women. Br J Nutr. 2015;113(2):350–65. doi: 10.1017/S0007114514003754 [DOI] [PubMed] [Google Scholar]
  • 35.Bravaccio C, Terrone G, Rizzo R, Gulisano M, Tosi M, Curatolo P, et al. Use of nutritional supplements based on melatonin, tryptophan and vitamin B6 (Melamil Tripto®) in children with primary chronic headache, with or without sleep disorders: a pilot study. Minerva Pediatr. 2020;72(1):30–6. doi: 10.23736/S0026-4946.19.05533-6 [DOI] [PubMed] [Google Scholar]
  • 36.Chaves Filho AJM, Lima CNC, Vasconcelos SMM, de Lucena DF, Maes M, Macedo D. IDO chronic immune activation and tryptophan metabolic pathway: A potential pathophysiological link between depression and obesity. Prog Neuropsychopharmacol Biol Psychiatry. 2018;80(Pt C):234–49. doi: 10.1016/j.pnpbp.2017.04.035 [DOI] [PubMed] [Google Scholar]
  • 37.Comai S, Bertazzo A, Brughera M, Crotti S. Tryptophan in health and disease. Adv Clin Chem. 2020;95:165–218. doi: 10.1016/bs.acc.2019.08.005 [DOI] [PubMed] [Google Scholar]
  • 38.Crotti S, Fraccaro A, Bedin C, Bertazzo A, Di Marco V, Pucciarelli S, et al. Tryptophan Catabolism and Response to Therapy in Locally Advanced Rectal Cancer (LARC) Patients. Front Oncol. 2020;10:583228. doi: 10.3389/fonc.2020.583228 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Maria NI, van Helden-Meeuwsen CG, Brkic Z, Paulissen SM, Steenwijk EC, Dalm VA, et al. Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren’s Syndrome. Arthritis Rheumatol. 2016;68(7):1688–99. doi: 10.1002/art.39629 [DOI] [PubMed] [Google Scholar]
  • 40.Choudhary AK, Lee YY. Neurophysiological symptoms and aspartame: What is the connection? Nutr Neurosci. 2018;21(5):306–16. doi: 10.1080/1028415X.2017.1288340 [DOI] [PubMed] [Google Scholar]
  • 41.Margaretten M. Neurologic Manifestations of Primary Sjögren Syndrome. Rheum Dis Clin North Am. 2017;43(4):519–29. doi: 10.1016/j.rdc.2017.06.002 [DOI] [PubMed] [Google Scholar]
  • 42.Li J, Che N, Xu L, Zhang Q, Wang Q, Tan W, et al. LC-MS-based serum metabolomics reveals a distinctive signature in patients with rheumatoid arthritis. Clin Rheumatol. 2018;37(6):1493–502. doi: 10.1007/s10067-018-4021-6 [DOI] [PubMed] [Google Scholar]
  • 43.Christgen SL, Becker DF. Role of Proline in Pathogen and Host Interactions. Antioxid Redox Signal. 2019;30(4):683–709. doi: 10.1089/ars.2017.7335 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Yue R, Zhao L, Hu Y, Jiang P, Wang S, Xiang L, et al. Metabolomic study of collagen-induced arthritis in rats and the interventional effects of huang-lian-jie-du-tang, a traditional chinese medicine. Evid Based Complement Alternat Med. 2013;2013:439690. doi: 10.1155/2013/439690 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Yamazaki M, Kitamura R, Kusano S, Eda H, Sato S, Okawa-Takatsuji M, et al. Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjögren’s syndrome patients with pulmonary involvements. Clin Exp Immunol. 2005;139(3):558–68. doi: 10.1111/j.1365-2249.2004.02704.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Tanaka T, Warner BM, Odani T, Ji Y, Mo YQ, Nakamura H, et al. LAMP3 induces apoptosis and autoantigen release in Sjögren’s syndrome patients. Sci Rep. 2020;10(1):15169. doi: 10.1038/s41598-020-71669-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Karabulut G, Kitapçıoğlu G, Özçaka Ö, Alpöz E, Nalbantsoy A, Koçanaoğulları H, et al. Saliva levels of caspase-1, TNF-α, and IFN-γ in primary Sjögren’s syndrome: oral mucosal abnormalities revisited. Turk J Med Sci. 2018;48(3):554–9. doi: 10.3906/sag-1710-31 [DOI] [PubMed] [Google Scholar]
  • 48.Alberich R, Castro JA, Llabrés M, Palmer-Rodríguez P. Metabolomics analysis: Finding out metabolic building blocks. PLoS One. 2017;12(5):e0177031. doi: 10.1371/journal.pone.0177031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Yu J, Chen Y, Li M, Gao Q, Peng Y, Gong Q, et al. Paeoniflorin down-regulates ATP-induced inflammatory cytokine production and P2X7R expression on peripheral blood mononuclear cells from patients with primary Sjögren’s syndrome. Int Immunopharmacol. 2015;28(1):115–20. doi: 10.1016/j.intimp.2015.05.023 [DOI] [PubMed] [Google Scholar]
  • 50.Lester S, Stokes L, Skarratt KK, Gu BJ, Sivils KL, Lessard CJ, et al. Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary Sjögren’s syndrome. Arthritis Res Ther. 2013;15(4):R71. doi: 10.1186/ar4248 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Finer S, Saravanan P, Hitman G, Yajnik C. The role of the one-carbon cycle in the developmental origins of Type 2 diabetes and obesity. Diabet Med. 2014;31(3):263–72. doi: 10.1111/dme.12390 [DOI] [PubMed] [Google Scholar]
  • 52.Walker AK. 1-Carbon Cycle Metabolites Methylate Their Way to Fatty Liver. Trends Endocrinol Metab. 2017;28(1):63–72. doi: 10.1016/j.tem.2016.10.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Kang JH, Lin HC. Comorbidities in patients with primary Sjogren’s syndrome: a registry-based case-control study. J Rheumatol. 2010;37(6):1188–94. doi: 10.3899/jrheum.090942 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Timothy J Garrett

1 Mar 2022

PONE-D-21-33918

Analysis of the saliva metabolic signature in patients with primary Sjögren's syndrome

PLOS ONE

Dear Dr. Li,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please carefully review the comments provided from the reviewer and respond to each statement.  It will be important to consider each statement and make the necessary revisions.  

Please submit your revised manuscript by Apr 11 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Timothy J Garrett, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

4. Please upload a new copy of Figure 3 as the detail is not clear. Please follow the link for more information: https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/" https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments (if provided):

I apologize for the delay in handling this manuscript. It was very difficult to find reviewers for the article. In the end, I have only received 1 review. Please carefully review the comments from the reviewer and provide a response to each point.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

********** 

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

********** 

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

********** 

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

********** 

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: PONE-D-21-33918

Li et al. studied that saliva metabolic profiling to explore changes in metabolite profiles and identify unique biomarkers for Sjögren’s syndrome (pSS). Although, this is an interesting work but there several issues that need to be addressed.

Major points:

1. In abstract section, objective need to be specific for biomarker analysis for Sjögren’s syndrome (pSS)

2. Sample were centrifuged at 1500g for 15min, what is the basis for doing this. Saliva contains lots of other matrix including food particles. How does it helps to get rid of these contaminates?

3. Is there any pre-normalization process for saliva? If not please explain how it conducted and how it will control the sample variation?

4. In several places, citation was not provided to locate the proper information. For example – “Raw data files were processed by Progenesis QI (Version 2.0, Nonlinear Dynamics) software based on a previously published identification strategy.” – there should be a reference that need to be add here.

5. MetaboAnalyst 5.0 is currently up-to-date version, why did author choose MetaboAnalyst 3.0 instead of latest version?

6. It was mentioned that QC was done by specialist, this is very generalized word. It need to be clearly stated that what is this specialist mean here?

7. In Figure 2A, author talked about the PCA analysis but in Figure 2B oPLS-DA, it is important to mention the PLS-DA Q2 model value to show the robustness of clustering for differential metabolite analysis.

8. 676 features with a P value < 0.05 were submitted for pathway enrichment analysis using the Mummichog algorithm, are these upregulated or downregulated or combined features? No information mentioned here.

9. Fig 3 claimed all the pathways are upregulated. It can be only possible if upregulated metabolites used for pathway analysis. It is confusing to read and connect with the biology otherwise. Please revisit the data and state this clearly.

10. Figure 4 heatmap clearly represent the challenge of saliva normalization, although it is difficult to do proper pre-normalization of saliva, but it will be greatly appreciated if the author could explain this limitation carefully.

11. Figure 4 is currently provided as customized and supervised manner. It is important to provide this figure with sample vs feature by unsupervised cluster so that top feature can be better understood.

12. Author claimed so many dipeptides are upregulated. Does it mean elevated protein degradation with the disease? Further follow up is missing in the discussion.

13. Targeted validation of claimed biomarker is missing.

Minor points:

1. Proper punctuation missing for several sentences: for example

“Saliva is a complex fluid containing a variety of metabolites, proteins, mRNAs, DNAs, enzymes, hormones, antibodies, antimicrobial constituents, growth factors and other molecules that may be associated with disease phenotypes [10, 11],” – it shouldn’t be comma. Likewise, several places there are missing of proper punctuation.

2. Overall, most of the figures need to provide with high resolution. Their current format is obscure.

********** 

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jun 2;17(6):e0269275. doi: 10.1371/journal.pone.0269275.r002

Author response to Decision Letter 0


9 Apr 2022

Dear Editor,

Thank you for carefully reviewing our manuscript previously titled “Analysis of the saliva metabolic signature in patients with primary Sjögren's syndrome” for possible publication in PLoS One. We are grateful to you and your reviewers for their constructive critique. We have revised the manuscript, highlighting our revisions in yellow, and have attached point-by-point responses detailing how we have revised the manuscript in response to the reviewers' comments below.

Thank you for your consideration and further review of our manuscript. Please do not hesitate to contact us with any further questions or recommendations.

Yours Sincerely,

Qian Li

Reviewer Comments:

Reviewer #1:

1. In abstract section, objective need to be specific for biomarker analysis for Sjögren’s syndrome (pSS)

Response: Thanks very much for your comments. As you suggested,abstract section had been added to the revised manuscript as follows.

Abstract section: “

Background

The saliva metabolome has been applied to explore the disease biomarkers. In this study we aim to characterize the metabolic profile of Primary Sjögren’s Syndrome (pSS) patients and explore the metabolomic biomarkers.” (Page 2, Line 2-5)

2. Sample were centrifuged at 1500g for 15min, what is the basis for doing this. Saliva contains lots of other matrix including food particles. How does it helps to get rid of these contaminates?

Response: Thanks very much for your comments. In our study, the unstimulated saliva sample collection was conducted at the same time of day (09:00–11:00 a.m.) to overcome any circadian influences. The subjects were requested to refrain from eating, drinking, smoking or oral hygiene procedures for at least 1.5 hr prior to saliva collection, and to rinse their mouth with water just prior to sample collection. This operation can minimize matrix including food particles in saliva. Then the samples were centrifuged at 1500 × g for 15 min at 4°C to remove exshed cell debris and residue, which might be helpful to get rid of food contaminates.

Previous investigators also used the similar saliva collection process (ref: Metabolomics analysis of saliva from patients with primary Sjögren's syndrome. Clin Exp Immunol. 2015;182(2):149-53.). We have added the above statement and reference to the manuscript as follows:

Materials and methods section: “ The samples were transported to the laboratory on ice and centrifuged at 1500 × g for 15 min at 4°C to remove shed cell debris and residue, and then the supernatants were frozen immediately and stored at -80°C until analysis[23].”(Page 7, Line 8-10)

3. Is there any pre-normalization process for saliva? If not please explain how it conducted and how it will control the sample variation?

Response: Thanks very much for your comments. Reliable identification of features distinguishing biological groups in salivary metabolite fingerprints requires the control of total metabolite abundance. Normalizations to one index values (for example, creatinine for urine metabolomics), osmolality, and total compound (useful MS signals) were the commonly used normalization techniques for overcoming sample variability in fluids metabolomics. Previous researches have compared the effect of different normalization method on urine metabolomics study. It showed that the best performance was normalization to the total compound. The approach does not only correct for different urinary output, but it also accounts for injection variability (Anal Bioanal Chem (2016) 408:8483-8493. DOI 10.1007/s00216-016-9974-1). S, Journal of Chromatography B. 2009, 877(5–6),).

According to above references, in present study, we normalized the data using the method of “Normalize to the total compound”. The detailed normalization method was as follows:

1) Normalization reference (the 'target'): one run is automatically selected as the normalization reference.

2) Log10 ratio calculation: for every run, a ratio can be taken for the value of the compound ion abundance in that run to the value in the normalization reference. This ratio calculation removes the influence of absolute abundance from the process, which is a major advantage over total-abundance-based methods.

3) Scalar estimation in log space: the next step is to center the log10 ratio distributions onto that of the normalization reference in each case.

4) Scalar application: once the scalar has been derived in log space and then returned to an ‘abundance-space ratio’, it can be applied to all values in the sample run being normalized, and this completes the process.”

We have added above statements in the manuscript (Page 8, Line 18; Page18, Line 13-21)

4. In several places, citation was not provided to locate the proper information. For example – “Raw data files were processed by Progenesis QI (Version 2.0, Nonlinear Dynamics) software based on a previously published identification strategy.” – there should be a reference that need to be add here.

Response: Thanks very much for your comments. We have added the references in the text “

Statistical Analysis

Raw data files were processed by Progenesis QI (Version 2.0, Nonlinear Dynamics) software based on a previously published identification strategy, which included sample alignment, peak picking, peak grouping, deconvolution, normalization by total compounds, and final information export (ref:An intelligentized strategy for endogenous small molecules characterization and quality evaluation of earthworm from two geographic origins by ultra-high performance HILIC/QTOF MS(E) and Progenesis QI.Anal Bioanal Chem. 2016 May;408(14):3881-90.) ” (Page 8 ,line 15-19)

5. MetaboAnalyst 5.0 is currently up-to-date version, why did author choose MetaboAnalyst 3.0 instead of latest version?

Answer: Thanks for the reviewer’s suggestion. The data was analyzed MetaboAnalyst 3.0. MetaboAnalyst version 5.0 aimed to narrow the gap from raw data to functional insights for global metabolomics based on high-resolution mass spectrometry (HRMS). And we re-analyzed the function pathway using MetaboAnalyst 5.0 and got the similar results to those using MetaboAnalyst 3.0 (FigR1).

In the revised manuscript we have updated the results (Figure 3).

Fig R1.Analysis results using MetaboAnalyst 3.0 (A) and MetaboAnalyst 5.0 (B).

6. It was mentioned that QC was done by specialist, this is very generalized word. It need to be clearly stated that what is this specialist mean here?

Response: Thanks very much for the reviewer’s suggestion. The “specialist”means the professionals these who have received professional LC/MS/MS analysis training. We have revised “specialist” as “professionals ” (Page 11 , line 17)

7. In Figure 2A, author talked about the PCA analysis but in Figure 2B oPLS-DA, it is important to mention the PLS-DA Q2 model value to show the robustness of clustering for differential metabolite analysis.

Response: Thanks for the reviewer’s suggestion. We have added the Q2 value and the CV-ANOVA p value of OPLS-DA model to validate the robustness of the model. And further permutation test was performed to ensure no overfitting of this model (intercept of Q2 = - 0.261).

We have added these statements in the mansucript “the OPLS-DA model achieved better separation for differential metabolite selection (R2X=0.413, R2Y=0.932, Q2=0.46, CV-ANOVA, p = 0.00070, Fig 2B). Permutation tests (100 times) were performed to confirm the stability and robustness of the supervised models presented in this study (intercept of Q2 = - 0.261, Supplementary Figure 1B).” (Page 12 , line 6-10)

8. 676 features with a P value < 0.05 were submitted for pathway enrichment analysis using the Mummichog algorithm, are these upregulated or downregulated or combined features? No information mentioned here.

Response: Thanks for the reviewer’s suggestion. We have added the information in the manuscript “Overall, 676 features with a P value < 0.05 (351 upregulated and 325 downregulated features) were submitted for pathway enrichment analysis using the Mummichog algorithm.” (Page 12 , line 11)

9. Fig 3 claimed all the pathways are upregulated. It can be only possible if upregulated metabolites used for pathway analysis. It is confusing to read and connect with the biology otherwise. Please revisit the data and state this clearly.

Response: Thanks for the reviewer’s suggestion. We have carefully checked the change trend of differential features enriched in these pathways. Metabolites involved in Tryptophan metabolism, Aspartate and asparagine metabolism showed up-regulated. And metabolites involved in Carbon fixation showed down-regulated.

We have revised the statements in the manuscript “Metabolites involved in tryptophan metabolism and aspartate and asparagine metabolism were upregulated. Metabolites involved in carbon fixation were downregulated(Fig 3)” (Page 12 ,line 15-17)

10. Figure 4 heatmap clearly represent the challenge of saliva normalization, although it is difficult to do proper pre-normalization of saliva, but it will be greatly appreciated if the author could explain this limitation carefully.

Response: Thanks for the reviewer’s suggestion. Pre-normalization of saliva is indeed a difficult problem.

The concentrations of endogenous metabolites in salivary vary widely and normalizing for these effects is necessary. Reliable identification of features distinguishing biological groups in salivary metabolite fingerprints requires the control of total metabolite abundance. Normalizations to one index values (for example, creatinine for urine metabolomics normalization), osmolality, and total compound (useful MS signals) were the commonly used normalization techniques for overcoming sample variability in fluids metabolomics (Warrack et al., 2009). Researches have compared the effect of different normalization method on urine metabolomics study. It showed that the best performance was from normalization to the total compound. The approach does not only correct for different urinary output, but it also accounts for injection variability (Warrack et al., 2009; Vogl et al., 2016). Thus, in present study, we normalized the data using the method of “Normalize to the total compound”. However, it cannot completely solve the problem of pre-normalization. It is necessary to perform targeted and absolute quantitative analysis to solve this problem, which is our future project.

We have added above statements in the discussion section

“Whole saliva is a complex fluid containing a variety of substances, and changes in the levels of these substances are related to the pathogenesis of various diseases. However, the function of the salivary glands in patients with pSS is severely weakened, resulting in the volume of saliva being too small. Patients' whole saliva up to 2 ml was collected for analysis over time to obtain a pre-normalization of saliva.

Reliable identification of features distinguishing biological groups in salivary metabolite fingerprints requires the control of total metabolite abundance. Normalizations to one index values (for example, creatinine for urine metabolomics), osmolality, and total compound (useful MS signals) were the commonly used normalization techniques for overcoming sample variability in fluids metabolomics. Previous researches have compared the effect of different normalization method on urine metabolomics study. It showed that the best performance was normalization to the total compound. The approach does not only correct for different urinary output, but it also accounts for injection variability (REF:Evaluation of dilution and normalization strategies to correct for urinary output in HPLC-HRTOFMS metabolomics.). In present study, we normalized the data using the method of “Normalize to useful MS signals” to reduce sample variation. However, it cannot completely solve the problem of pre-normalization. It is necessary to perform targeted and absolute quantitative analysis to solve this problem, which is our future project. ” (Page 18, line 8-21)

11. Figure 4 is currently provided as customized and supervised manner. It is important to provide this figure with sample vs feature by unsupervised cluster so that top feature can be better understood.

Response: Thanks for the reviewer’s suggestion. we have plotted this figure with sample vs feature by unsupervised cluster as following, and the results showed the metabolites could distinguish the pSS subjects and healthy controls.

Fig R4 Relative intensity of differential metabolites in pSS subjects and healthy controls

12. Author claimed so many dipeptides are upregulated. Does it mean elevated protein degradation with the disease? Further follow up is missing in the discussion.

Response: Thanks very much for your comments. We have added a note to the discussion,

“We noticed that many dipeptides are upregulated. Lysosomal pathway, ubiquitination pathway, and caspase pathway are major pathways of protein degradation. Lysosome-associated membrane protein 3(LAMP3) is classically associated with the lysosome, a main organelle central to autophagy. Previous study reported that In Sjogren's syndrome cases, the expression of LAMP3 was increased, which was related to apoptosis.(ref: LAMP3 induces apoptosis and autoantigen release in Sjögren's syndrome patients. 2020 Sep 16;10(1):15169. ). For caspase pathway previous studies found that saliva levels of caspase-1 were significantly higher in SS patients , which can induce the production of apoptosis(ref: Saliva levels of caspase-1, TNF-α, and IFN-γ in primary Sjögren's syndrome: oral mucosal abnormalities revisited. Turk J Med Sci, 2018 Jun 14;48(3):554-559.). According to above studies, several important protein degradation pathways in SS were up-regulated. Therefore, it was possible that protein degradation was increased in SS, which lead to more dipeptides.”(Page 21 ,line 6-15)

13. Targeted validation of claimed biomarker is missing.

Response: Thanks for the reviewer’s suggestion. This work was a pilot study for SS metabolic biomarker analysis. We totally agree with the reviewer’s suggestion that targeted validation of claimed biomarker with more samples is necessary. We are trying to collect samples from multiple centers, and to validate the metabolic biomarkers. We will present validation work in the future. We have added above statements in the manuscript “This work was a pilot study for SS metabolic biomarker analysis. Further studies should expand the number of pSS patient samples and validate the potential metabolite biomarkers using targedted method, which is our future work.”(Page23, Line 2-4)

Minor points:

1. Proper punctuation missing for several sentences

Response: Thanks very much for your comments. We have carefully examined the punctuation and the letter case.

2. Overall, most of the figures need to provide with high resolution. Their current format is obscure.

Response: Thanks very much for your comment. We have re-uploaded the figures with higher definition and resolution and hope these figures will meet the requirement.

Attachment

Submitted filename: Response to Reviewers.doc

Decision Letter 1

Timothy J Garrett

18 May 2022

Analysis of the saliva metabolic signature in patients with primary Sjögren's syndrome

PONE-D-21-33918R1

Dear Dr. Li,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Timothy J Garrett, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Timothy J Garrett

23 May 2022

PONE-D-21-33918R1

Analysis of the saliva metabolic signature in patients with primary Sjögren's syndrome

Dear Dr. Li:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Timothy J Garrett

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig

    (a) Tight clustering of QC samples indicated good stability of the analysis. (b) Platform 100 times permutation tests for the OPLS-DA model.

    (TIF)

    S1 Table. The metabolites related with pSS/control.

    Fold change > 1 indicates a relatively higher concentration of the marker present in pSS patients, whereas < 1 indicates a relatively lower concentration of the marker compared with healthy control subjects.

    (DOCX)

    S2 Table. Receiver operating characteristic (ROC) analysis of potential pSS biomarkers.

    Note: The sensitives and specificities were calculated at their best cutoff points.

    (DOCX)

    S1 File. PLOS One clinical studies checklist.

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers.doc

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES